Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4173460 | 0.87 | POLB (0.39) | SCN9APOLBNPSR1CYP2C9 | |
| SCHEMBL4178014 | 0.85 | PIK3CD (0.50) | ATMPIK3CD | |
| SCHEMBL4181249 | 0.82 | ATM (0.56) | ATMPIK3CD | |
| SCHEMBL1596806 | 0.82 | ATM (0.48) | ATMPIK3CDHSD11B1 | |
| SCHEMBL1597913 | 0.80 | ATM (0.51) | ATMPIK3CDPOLB | |
| SCHEMBL1891693 | 0.79 | PIK3CD (0.47) | ATMS1PR1SCN9APIK3CD | |
| SCHEMBL1883149 | 0.79 | PIK3CD (0.47) | ATMS1PR1SCN9APIK3CD | |
| SCHEMBL4180752 | 0.79 | PIK3CD (0.53) | ATMPIK3CDPOLB | |
| SCHEMBL4182705 | 0.78 | ATM (0.55) | ATMPIK3CD | |
| SCHEMBL12728069 | 0.77 | ATM (0.48) | ATMPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399483-B2 | Quinoxaline and quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2013-03-19 | — | — | US | disclosed |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA, S.A. (BE) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | PDXK, PDPK1, PIKFYVE | ATM 545/4885S1PR1 2707/4885SCN9A 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.